Our drug discovery and development process begins with our Genome5000™ program.  We utilize our mouse gene knockout technologies and state-of-the-art medical analyses to discover the physiological and behavioral functions of the most druggable mammalian genes.  Through this program, we have identified the physiological functions of nearly 5,000 genes and we have validated more than 100 drug targets.  By integrating this genetic knowledge with our medicinal chemistry and antibody development capabilities, we have created a unique, growing clinical pipeline. 

Our goal is to enhance the lives of patients by discovering and developing breakthrough treatments for human disease.  We believe that our systematic, genetics-driven approach will enable us to substantially expand our clinical pipeline to achieve successful commercialization of important new medicines.